Doudna’s new mission; Aclaris CEO to step down; Tome’s $114M liver dysfunction take care of Genevant
Plus, information about Orion, Stalicla, Cyrano Therapeutics and Instil Bio: Jennifer Doudna’s latest venture: Her lab published a find out about Thursday in Nature Biotechnology detailing how antiframe fragments can be utilized